Form 4: Centessa Pharmaceuticals Acquisition Completed

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders set to receive cash and contingent value rights.

Summary

• Centessa Pharmaceuticals plc has been acquired by Eli Lilly and Company through a scheme of arrangement.
• The transaction, effective June 24, 2026, involved Eli Lilly's subsidiary, LDH XV Corporation, acquiring all outstanding ordinary shares.
• Shareholders are entitled to receive $38.00 in cash per ordinary share, plus one non-transferable contingent value right (CVR) per ordinary share.
• The CVR offers potential contingent payments of up to an additional $9.00 per ordinary share, dependent on the achievement of specified milestones.
• Index Ventures Life VI (Jersey) L.P., Yucca (Jersey) SLP, and Index Venture Life Associates VI Ltd are identified as reporting persons with significant ownership stakes.
• These entities disclaim beneficial ownership beyond their pecuniary interest, as the transfer of shares occurred automatically via the scheme of arrangement.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for Centessa shareholders, as the acquisition provides a guaranteed cash payout and the potential for additional value through CVRs, indicating a successful exit for investors.

Positives

• Shareholders will receive a cash payment of $38.00 per share, providing immediate value.
• The inclusion of a contingent value right (CVR) offers the potential for additional future payments up to $9.00 per share if specific milestones are met.

Negatives

• The ordinary shares of Centessa Pharmaceuticals plc will no longer be publicly traded following the acquisition.
• The CVR payments are contingent and not guaranteed, meaning shareholders may not receive the full potential additional value.

Risks

• The achievement of milestones for the contingent value rights (CVRs) is not guaranteed, posing a risk to the full realization of potential shareholder value.
• The reporting persons disclaim beneficial ownership beyond their pecuniary interest, which could indicate complex ownership structures or potential future disputes.

Future Outlook

The future outlook for Centessa Pharmaceuticals plc as an independent entity is concluded due to the acquisition. Future value for former shareholders is tied to the contingent payments associated with the CVRs, which depend on the achievement of specified milestones.

Management Comments

• The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Persons.
• The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Index Ventures Life VI, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose.
• The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Yucca, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose.

Industry Context

StockSavvy.ai notes that this Form 4 filing confirms the completion of a significant acquisition in the pharmaceutical sector, reflecting a trend of consolidation driven by larger companies seeking to expand their pipelines and market presence. The structure involving cash and contingent value rights is a common mechanism in such deals to bridge valuation gaps and incentivize future performance.

Stakeholder Impact

• Shareholders: Will receive $38.00 cash per share and a CVR with potential for additional payments, marking the end of their direct investment in Centessa Pharmaceuticals plc.
• Employees: Their future employment status and roles will be determined by Eli Lilly and Company following the acquisition.
• Creditors: The acquisition by Eli Lilly, a financially strong entity, likely provides a stable outlook for outstanding debts of Centessa Pharmaceuticals plc.

Next Steps

• Shareholders of Centessa Pharmaceuticals plc will receive $38.00 in cash per ordinary share.
• Shareholders will also receive one non-transferable contingent value right (CVR) per ordinary share, with potential payments up to $9.00 per share upon achievement of specified milestones.

Key Dates

Keywords

Centessa Pharmaceuticals, Eli Lilly, Acquisition, Scheme of Arrangement, Form 4, SEC Filing, Ordinary Shares, Contingent Value Right, Index Ventures, Merger